|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
02877 SHINEWAY PHARM
Nominal 
8.410 +0.080 (+0.960%) | 2023/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | 2019/12 RMB(K¥) | |
| Turnover | 4,516,538 | 14.324% | 3,950,636 | 3,223,550 | 2,655,701 | 2,705,996 |
| Cost of Sales | (1,122,419) | 10.876% | (1,012,322) | (813,214) | (667,855) | (724,431) |
| Gross Profit | 3,394,119 | 15.512% | 2,938,314 | 2,410,336 | 1,987,846 | 1,981,565 |
| 2023/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | 2019/12 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | (4,073) | -- | |
| Change in FV & Impairment on Others | (5,440) | -38.378% | (8,828) | (7,021) | (232,443) | (44,647) | |
| Profit / (Loss) on Disposal | -- | -- | -- | -- | -- | -- | |
| Other Non-operating Items | -- | -- | -- | -- | -- | -- | |
| Share of Results of Asso. & JCEs | 0 | -- | 0 | 0 | 0 | 0 | |
| Profit / (Loss) before Taxation | 1,240,253 | 35.247% | 917,025 | 720,103 | 395,024 | 642,772 | |
| Taxation | (270,743) | 39.377% | (194,252) | (163,429) | (99,991) | (139,622) | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | 0 | -- | 0 | 0 | 0 | 0 | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | 969,510 | 34.138% | 722,773 | 556,674 | 295,033 | 503,150 | |
| 2023/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | 2019/12 RMB(K¥) | |
| Net Finance Costs / (Income) | (92,470) | 0.729% | (91,801) | (93,812) | (71,226) | (80,302) |
| Depreciation & Amortisation | 60,233 | 2.636% | 58,686 | 63,661 | 49,160 | 53,350 |
| Directors' Emoluments | 42,317 | 257.136% | 11,849 | 10,319 | 9,153 | 12,262 |
| 2023/12 - Final | %Chg (Compare to Final) | 2022/12 | 2021/12 | 2020/12 | 2019/12 | |
| Auditor's Opinion Status | Unqualified | -- | Unqualified | Unqualified | Unqualified | Unqualified |
Market Valuation Indicators
| 2023/12 - Final | %Chg (Compare to Final) | 2022/12 | 2021/12 | 2020/12 | 2019/12 | |
| EPS (cts) | 128.000 | 33.333% | 96.000 | 74.000 | 39.000 | 64.000 |
| DPS (cts) | 42.000 | -- | 32.000 | 39.000 | 32.000 | 32.000 |
| Dividend Payout Ratio (%) | 32.813% | -- | 33.333% | 52.703% | 82.051% | 50.000% |
| Cash flow per share ($) | 1.235 | -- | 1.469 | 0.931 | 0.844 | 0.471 |
| NBV per share ($) | 8.506 | -- | 7.718 | 7.136 | 7.006 | 6.985 |
| Remarks: | Real time quote last updated: 15/11/2024 17:59 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (K¥) | RMB 626,479 |
| %Change | 27.472% |
| EPS / (LPS) | RMB 0.830 |
| NBV Per Share (¥) | RMB 8.871 |